Biotech | December 24, 2021
Lecanemab granted Fast Track designation by the U.S. FDA
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Authorized booster increases Omicron neutralizing antibody levels approximately 37-fold
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Subscribe To Our Newsletter & Stay Updated
